医学
哮喘
肺癌
内科学
危险系数
全国健康与营养检查调查
比例危险模型
置信区间
人口
环境卫生
作者
Jiatao Li,Huanhuan Liu,Bing Xu
标识
DOI:10.3389/fnut.2025.1525115
摘要
Background Asthma poses a significant global health challenge, representing a chronic respiratory disorder marked by airway inflammation. The advanced lung cancer inflammation index (ALI) served as a comprehensive index to assess inflammation. However, few studies have investigated the association between ALI and both all-cause and cardiovascular mortality in US patients with asthma. Methods We used data from the National Health and Nutrition Examination Survey (NHANES) to explore the association of ALI with all-cause and cardiovascular mortality in US patients with asthma. This study used Kaplan–Meier curves to examine the ALI index's impact on asthma patients' survival. We applied weighted Cox models and restricted cubic splines (RCS) analysis to assess the ALI-mortality link, identifying non-linear thresholds with a recursive algorithm. Subgroup analyses and sensitivity analyses were conducted, excluding those with missing covariates and cancer patients. Results A total of 6,211 asthma patients were enrolled and categorized into three groups based on ALI tertiles. The risk of all-cause mortality decreased as ALI increased in the fully adjusted multivariate Cox regression analysis; the hazard ratio (HR) is 0.95 (95% CI: 0.91–0.99, P = 0.01). Compared with the lowest ALI group, T1, the fully adjusted HR values for ALI and all-cause mortality in T2, T3 were 0.68 (95% CI: 0.55–0.85, P < 0.001), 0.53 (95% CI: 0.41–0.68, P < 0.001). The risk of cardiovascular mortality was also lower in the groups of T2 (HR: 0.84, 95% CI: 0.55–1.28) and T3 (HR: 0.47, 95% CI: 0.31–0.71, P for trend < 0.001), respectively. In addition, the results of the subgroup analyses were robust. Conclusions This cohort study demonstrated the higher accuracy of ALI in predicting mortality in asthma patients, highlighting its important clinical value of ALI in risk assessment and prognosis evaluation.
科研通智能强力驱动
Strongly Powered by AbleSci AI